Get the Stockscreener App
7.6369
7.27%
-0.6131
Aligos Therapeutics Inc stock is traded at $7.6369, with a volume of 71,521.
It is down -7.27% in the last 24 hours and down -24.03% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$8.25
Open:
$8.28
24h Volume:
71,521
Relative Volume:
0.90
Market Cap:
$40.87M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.3145
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
-21.70%
1M Performance:
-24.03%
6M Performance:
+36.61%
1Y Performance:
-19.90%
1-Day Range:
$7.4526
$8.469
1-Week Range:
$7.4526
$10.06
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.6369 | 57.35M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.99 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.60 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.15 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.38 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.77 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Is Aligos Therapeutics Inc. (5WK0) stock resilient in recession scenarios2025 Performance Recap & Comprehensive Market Scan Insights - newser.com
How to build a dashboard for Aligos Therapeutics Inc. stock2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
When is the best time to exit Aligos Therapeutics Inc.Trade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Why Aligos Therapeutics Inc. stock remains on buy listsJuly 2025 Patterns & Weekly Top Stock Performers List - newser.com
How buybacks impact Aligos Therapeutics Inc. stock valueMarket Growth Report & Weekly High Potential Stock Alerts - newser.com
How to forecast Aligos Therapeutics Inc. trends using time series2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Multi factor analysis applied to Aligos Therapeutics Inc.Dollar Strength & Safe Investment Capital Preservation Plans - newser.com
How Aligos Therapeutics Inc. (5WK0) stock stacks up against competitorsEarnings Recap Report & Free High Return Stock Watch Alerts - newser.com
Is Aligos Therapeutics Inc a good long term investmentChart Pattern Recognition & Free Rapid Return Acceleration - earlytimes.in
Is Aligos Therapeutics Inc. stock positioned well for digital economy2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Aligos Therapeutics, Inc. (ALGS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Is Aligos Therapeutics Inc. stock supported by strong fundamentalsEarnings Overview Report & Precise Buy Zone Tips - newser.com
Published on: 2025-10-31 04:14:04 - newser.com
Is Aligos Therapeutics Inc. (5WK0) stock a fit for income portfoliosDollar Strength & Weekly Stock Performance Updates - newser.com
Is Aligos Therapeutics Inc. (5WK0) stock safe for risk averse investors2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Can Aligos Therapeutics Inc. (5WK0) stock double in coming yearsTrade Entry Report & Safe Capital Growth Plans - newser.com
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Aligos Therapeutics (Nasdaq: ALGS) to announce financial results Nov 6, 2025 - Stock Titan
Aligos Therapeutics (ALGS) Expected to Announce Earnings on Wednesday - MarketBeat
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):